Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 1 of 2 range targets
Below the range 1 below the last range given

The numbers ADMA said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2027
Given $455.00M release Jan 12, 2026
– No standard number
The company's words
FY 2027 Adjusted EBITDA expected to be approximately $455 million release Jan 12, 2026
Net income (company-defined)
Fiscal 2027
Given $315.00M release Jan 12, 2026
– No standard number
The company's words
FY 2027 Adjusted Net Income expected to be approximately $315 million release Jan 12, 2026
Revenue
Fiscal 2027
Given $775.00M release Jan 12, 2026
– Not reported yet
The company's words
FY 2027 total revenue expected to be approximately $775 million release Jan 12, 2026
EBITDA (company-defined)
Fiscal 2026
Given $360.00M release Jan 12, 2026
Lowered $265.00M to $300.00M release May 6, 2026
Kept $265.00M to $300.00M release Aug 5, 2026
– No standard number
The company's words
FY 2026 expected Adjusted EBITDA increased to approximately $360 million, up from $355 million previously release Jan 12, 2026
FY 2026 Adjusted EBITDA expected to be $265 million to $300 million release May 6, 2026
FY2026 Adjusted EBITDA expected to be $265 million to $300 million release Aug 5, 2026
Net income (company-defined)
Fiscal 2026
Given $255.00M release Jan 12, 2026
Lowered $170.00M to $200.00M release May 6, 2026
Kept $170.00M to $200.00M release Aug 5, 2026
– No standard number
The company's words
FY 2026 expected Adjusted Net Income reiterated at approximately $255 million release Jan 12, 2026
FY 2026 Adjusted Net Income expected to be $170 million to $200 million release May 6, 2026
FY2026 Adjusted Net Income expected to be $170 million to $200 million release Aug 5, 2026
Revenue
Fiscal 2026
Given $635.00M release Jan 12, 2026
Lowered $530.00M to $560.00M release May 6, 2026
Kept $530.00M to $560.00M release Aug 5, 2026
– Not reported yet
The company's words
FY 2026 expected total revenue increased to approximately $635 million, up from $630 million previously release Jan 12, 2026
FY 2026 total revenue expected to be $530 million to $560 million release May 6, 2026
FY2026 total revenue expected to be $530 million to $560 million release Aug 5, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $220.00M to $300.00M release Jan 13, 2025
Raised $235.00M to $340.00M release Aug 6, 2025
– No standard number
The company's words
FY 2025 and 2026 Adjusted EBITDA expected to exceed $220 million and $300 million, respectively release Jan 13, 2025
FY 2025 and 2026 Adjusted EBITDA reaffirmed to be more than $235 million and $340 million or more, respectively release Aug 6, 2025
Net income
Fiscal 2025 (ended Dec 31, 2025)
Given $170.00M to $230.00M release Jan 13, 2025
$146.93M
10-K filed 2026-02-25
Below the range
The company's words
FY 2025 and 2026 net income expected to exceed $170 million and $230 million, respectively release Jan 13, 2025
Net income (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $175.00M to $245.00M release Aug 6, 2025
– No standard number
The company's words
FY 2025 and 2026 Adjusted Net Income reaffirmed to be more than $175 million and $245 million or more, respectively release Aug 6, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $485.00M to $600.00M release Jan 13, 2025
Raised $500.00M to $625.00M release Aug 6, 2025
$510.17M
10-K filed 2026-02-25
Within the range
The company's words
FY 2025 and 2026 total revenue expected to exceed $485 million and $600 million, respectively release Jan 13, 2025
FY 2025 and 2026 total revenue reaffirmed to be more than $500 million and $625 million or more, respectively release Aug 6, 2025
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
  • Revenue, Fiscal 2024 (ended Dec 31, 2024): said $320.00M, reported $426.45M. The company's words

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.